A multicentre study reviewed 68 patients (mean age 74 years) treated with sunitinib for metastatic renal cell cancer. Fatigue (81%), mucositis (62%) and hypertension (59%) were common. Cardiac events occurred in 9 patients and therapy was stopped early in 10 patients owing to rapidly progressive disease or severe toxicity. Overall, sunitinib was effective, but a lower starting dose escalated in the absence of toxicity should be recommended.
ORIGINAL RESEARCH PAPER
Brunello, A. et al. Safety and efficacy of sunitinib in elderly patients (≥70 years) with metastatic renal cell carcinoma: a multicenter study. Ann. Oncol. doi:10.1093/annonc/mds431
Rights and permissions
About this article
Cite this article
Safety and efficacy of sunitinib in elderly patients. Nat Rev Urol 9, 671 (2012). https://doi.org/10.1038/nrurol.2012.209
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2012.209